While many are still in clinical trials, crizotinib (Xalkori), which targets the EML4-ALK oncogenic fusion gene indentified in NSCLC, was recently approved by the US Food and Drug Administration (FDA). Here, ALK is linked to non-small cell lung carcinoma.